| Name | Title | Contact Details |
|---|---|---|
Kristin Papesh |
Vice President - Human Resources | Profile |
Mary Hull |
Director - Human Resources Solutions - Payroll and HRIS | Profile |
Daniel Curoe |
Director - Human Resources | Profile |
Mark Salisbury |
Director - Human Resources | Profile |
Derek Zingg |
Director - Global Benefits | Profile |
ApiJect Systems, Corp. is reimagining how injectable medicines can be packaged and delivered to the world. ApiJect`s technology platform is based on a design philosophy of basic interlocking components to create simple and highly-scalable drug delivery devices. Our first product is the ApiJect Prefilled Injector, a single-dose parenteral that is manufactured in two parts: a Blow-Fill-Seal (BFS) Container aseptically filled with medicine or vaccine, and an insulin-style Needle Hub, also made by ApiJect. At the point of care, a healthcare worker attaches these two components in seconds to activate the injector. By using high-speed, high-volume Blow-Fill-Seal plastics technology, we can reliably supply millions of aseptically filled prefilled injectors per month. Simple devices like these will enable ApiJect to fulfill its mission of making injectable medicines safe and available for everyone.
Build Your Proactive Myopia Management Practice With Euclid Orthokeratology!Euclid Systems Corporation is a global leader in Advanced Orthokeratology and Proactive Myopia Management. Proven on millions of eyes around the world, Euclid Ortho-K lenses are designed for the individual patient`s eyes. Thanks to the power of Three Factor Fitting, integrating Euclid orthokeratology into your practice is easy! Simply provide three parameters: RX, K Readings, and HVID. This efficient, empirical process yields a category-leading 87%* first fit success. No trial lenses required. With headquarters in, Virginia, USA, Euclid manufactures all products exclusively in the United States with approval from the U.S. Food & Drug Administration (FDA). The company additionally has offices in Shanghai and Beijing, China, and is leading global efforts in myopia management in children.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
Mexpo International is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arnold Dental Supply Inc is a Lynnwood, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.